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Abstract: Associative memory can be rendered malleable by a reminder. Blocking the ensuing re-
consolidation process is suggested as a therapeutic target for unwanted aversive memories. Matrix met-
alloproteinase (MMP)-9 is required for structural synapse remodelling involved in memory consolidation.
Inhibiting MMP-9 with doxycycline is suggested to attenuate human threat conditioning. Here, we inves-
tigate whether MMP-9 inhibition also interferes with threat memory re-consolidation. N=78 male and
female human participants learned the association between two visual conditioned stimuli (CS+) and a
50% chance of an unconditioned nociceptive stimulus (US), and between CS- and the absence of US. On
day 7, one CS+ was reminded without reinforcement 3.5 hours after ingesting either 200 mg doxycy-
cline, or placebo. On day 14, retention of CS memory was assessed under extinction, by fear-potentiated
startle. Contrary to our expectations, we observed a greater CS+/CS- difference in participants who
were reminded under doxycycline, compared to placebo. Participants who were reminded under placebo
showed extinction learning during the retention test, which was not observed in the doxycycline group.
There was no difference between the reminded and the non-reminded CS+ in either group. In contrast,
during re-learning after the retention test, CS+/CS- difference was more pronounced in the placebo
than the doxycycline group. To summarize, a single dose of doxycycline appeared to have no specific
impact on re-consolidation, but to globally impair extinction learning, and threat re-learning, after drug
clearance.MMP-9 inhibition appears to attenuate memory consolidation. It could also be a target for
blocking reconsolidation. Here, we test this hypothesis in human threat conditioning. We find that doxy-
cycline has no specific impact on a reminded cue, but confers a global reduction in extinction learning
and threat learning beyond the clearance of the drug. This may point towards a more long-lasting impact
of doxycycline treatment on memory plasticity.
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Abstract  32 
Associative memory can be rendered malleable by a reminder. Blocking the ensuing re-33 
consolidation process is suggested as a therapeutic target for unwanted aversive memories. 34 
Matrix metalloproteinase (MMP)-9 is required for structural synapse remodelling involved in 35 
memory consolidation. Inhibiting MMP-9 with doxycycline is suggested to attenuate human 36 
threat conditioning. Here, we investigate whether MMP-9 inhibition also interferes with 37 
threat memory re-consolidation. N=78 male and female human participants learned the 38 
association between two visual conditioned stimuli (CS+) and a 50% chance of an 39 
unconditioned nociceptive stimulus (US), and between CS- and the absence of US. On day 7, 40 
one CS+ was reminded without reinforcement 3.5 hours after ingesting either 200 mg 41 
doxycycline, or placebo. On day 14, retention of CS memory was assessed under extinction, 42 
by fear-potentiated startle. Contrary to our expectations, we observed a greater CS+/CS- 43 
difference in participants who were reminded under doxycycline, compared to placebo. 44 
Participants who were reminded under placebo showed extinction learning during the 45 
retention test, which was not observed in the doxycycline group. There was no difference 46 
between the reminded and the non-reminded CS+ in either group. In contrast, during re-47 
learning after the retention test, CS+/CS- difference was more pronounced in the placebo 48 
than the doxycycline group. To summarize, a single dose of doxycycline appeared to have no 49 
specific impact on re-consolidation, but to globally impair extinction learning, and threat re-50 
learning, after drug clearance.  51 
 52 
Significance statement 53 
MMP-9 inhibition appears to attenuate memory consolidation. It could also be a target for 54 
blocking reconsolidation. Here, we test this hypothesis in human threat conditioning. We 55 
find that doxycycline has no specific impact on a reminded cue, but confers a global 56 
reduction in extinction learning and threat learning beyond the clearance of the drug. This 57 
may point towards a more long-lasting impact of doxycycline treatment on memory 58 
plasticity.  59 
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Introduction 60 
Recall can render associative memory malleable under suitable conditions (Nader et al., 61 
2000). Such labilised memory is thought to spontaneously stabilise in a re-consolidation 62 
process. This has been demonstrated by disrupting re-consolidation with local protein 63 
synthesis inhibition, which makes conditioned responding disappear (Nader et al., 2000). 64 
While extinction training also attenuates conditioned responding, the initial threat memory 65 
can re-emerge after passage of time, in a different context, or after non-predictable US 66 
presentations (Dunsmoor et al., 2015). This is not (or less so) the case for re-consolidation 67 
blockade, which thus appears to lastingly modify memory (Duvarci and Nader, 2004; Lin et 68 
al., 2006). Thus, re-consolidation blockade could be a potentially powerful principle for 69 
clinical treatment of unwanted aversive memories, such as the recollection of psychological 70 
trauma (Kindt, 2018). 71 
 72 
Because systemically administering protein synthesis inhibitors is not feasible, previous 73 
attempts to translate this approach to humans have capitalized on behavioural procedures 74 
such as reminder/extinction combination (Monfils et al., 2009; Schiller et al., 2010) or 75 
neurotransmitter-based mechanisms such as norepinephrine antagonists (Debiec and 76 
Ledoux, 2004; Kindt et al., 2009; Brunet et al., 2018). However, it may also be possible to 77 
interfere more directly with intrasynaptic signalling pathways to achieve this goal. 78 
Conceptually, re-consolidation could be a way of integrating new information into existing 79 
memory, and is therefore often thought to be similar to consolidation (McKenzie and 80 
Eichenbaum, 2011). Indeed, many (although not all) molecular and cellular features of 81 
consolidation and re-consolidation are shared (Besnard et al., 2012). Here, we focus on 82 
MMP-9, which is a key molecule in the consolidation pathway (Huntley, 2012) and can be 83 
targeted with human-approved drugs (Bach et al., 2018a).  84 
 85 
MMP-9 forms part of a signalling cascade that leads to the persistent structural changes in 86 
the synaptic configuration that underlie long-term potentiation (LTP) (Huntley, 2012). MMP 87 
inhibition or knock-out disrupts LTP in acute slices (Nagy et al., 2006; Meighan et al., 2007; 88 
Okulski et al., 2007; Wang et al., 2008; Gorkiewicz et al., 2015), while activated MMP-9 89 
induces LTP (Nagy et al., 2006; Wang et al., 2008). In vivo, MMP inhibition reduces spatial 90 
and contextual learning in non-human animals (Nagy et al., 2007; Knapska et al., 2013). 91 
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Translating these findings to humans is afforded by the antibiotic doxycycline, a broad-92 
spectrum MMP inhibitor (Hanemaaijer et al., 1998) that crosses the blood-brain barrier 93 
(Mento et al., 1969; Dotevall and Hagberg, 1989; Karlsson et al., 1996; Lucchetti et al., 2019). 94 
Using a standard delay discriminative threat conditioning protocol (also termed fear 95 
conditioning (LeDoux, 2014)), we have previously shown in humans that a single dose of 200 96 
mg doxycycline, administered orally about 210 minutes before a multiple-trial Pavlovian 97 
discriminative threat learning procedure, reduced retention of that memory on day 7 by 98 
about 60% (Bach et al., 2018a). This suggests that doxycycline interferes with acquisition 99 
and/or synaptic consolidation, consistent with an impact on LTP. If the synaptic mechanisms 100 
underlying consolidation and re-consolidation are to some extent similar, this raises a 101 
possibility that doxycycline may also interfere with synaptic re-consolidation. A rodent study 102 
yielded ambiguous evidence for this possibility: re-consolidation was disrupted after 103 
retrieval under MMP inhibition in animals that had undergone 4-trial threat conditioning 104 
(Brown et al., 2009). In the same report, however, there was no impact of MMP inhibition 105 
on synaptic consolidation in 1-trial Pavlovian threat conditioning (Brown et al., 2009). Here, 106 
we sought to demonstrate an impact of doxycycline on threat memory re-consolidation in 107 
humans.   108 
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Materials and Methods 109 
Participants 110 
Table 1: Demographic and performance characteristics of the final analysed sample 111 
 Placebo Doxycycline  
Sex 20 male 20 female 20 male 18 female       
Mean SD Mean SD p 
Age 24.4 4.84 25.3 4.97 .41 
STAI X1 34.8 6.89 35.70 5.68 .52 
STAI X2 37.1 6.40 38.4 5.41 .31 
BDI 3.74 4.35 3.19 3.27 .82 
US Current (mA) 3.87 1.06 3.97 1.54 .75 
US habituation during acquisition (rating difference) -5.21 13.6 -6.22 15.8 .86 
US habituation end of acquisition - end of re-learning (rating 
difference)1 
9.00 15.0 -7.2. 14.6 .62 
Accuracy acquisition 0.97 0.07 0.99 0.02 .11 
Accuracy reminder 0.93 0.27 0.87 0.34 .42 
Accuracy retention/re-learning 0.99 0.02 0.99 0.02 .96 
Performance acquisition (response rate) 0.99 0.01 1.00 0.01 .12 
Performance reminder (response rate) 0.97 0.16 0.97 0.16 .97 
Performance retention/re-learning (response rate) 1.00 0.00 1.00 0.01 .36 
RT acquisition (ms) 953 214 996 226 044 
RT retrieval (ms) 1186 607 1103 447 051 
RT retention/re-learning  (ms) 927 219 948 228 069 
Number of response training blocks required 1.55 1.08 1.44 0.55 060 
1Six participants were not included into analysis of the re-learning session (see Materials and Methods, Participants). SD: standard 112 
deviation. p: p-value from a two-sample, two-tailed t-test comparing the two groups. STAI: state-trait anxiety inventory. X1: state anxiety. 113 
X2: trait anxiety. BDI: Beck depression inventory. US: unconditioned stimulus. US habituation: average pain rating (0-100) difference. 114 
Accuracy: correct responses/total trials in incidental task. Performance: total responses/total trials in incidental task. RT: reaction time.  115 
 116 
Participants were recruited from the general population (n = 80; 40 per group; 20 female per 117 
group). One participant did not complete reminder visit 3 due to vomiting immediately after 118 
ingesting the drug. One further participant was excluded from analysis due to suspected 119 
alcohol consumption before retention visit 4. Re-including this participant into the analysis 120 
did not change the pattern of results. The reported final sample therefore comprised 78 121 
individuals, 40 in the placebo group and 38 in the doxcycline group (Figure 1a). The groups 122 
did not differ in age, gender, US current, depression, state anxiety, or trait anxiety (Table 1). 123 
Differences in US habituation and accuracy during acquisition were modelled as co-variates. 124 
All participants were screened for health conditions by a physician during visit 1 (see (Bach 125 
et al., 2018a) for in- and exclusion criteria).  126 
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The study was conducted in accord with the Declaration of Helsinki and approved by the 127 
governmental research ethics committee (Kantonale Ethikkomission Zurich, KEK-ZH 2014-128 
0669) and the Swiss Agency for Therapeutic Products (Swissmedic, 2015DR1136). All 129 
participants gave written informed consent using a form approved by the ethics committee. 130 
The study was pre-registered at the primary ISRCTN registry (ISRCTN66987216) and at the 131 
Swiss Federal Complementary Database (KOFAM; SNCTP000001439).  132 
 133 
Figure 1. Study design. A: CONSORT flow chart. B: Study procedures. C: Three CS were trained on day 0, of which two were reinforced with 134 
50% rate. On day +7, one of these - CS+r - was reminded without reinforcement. On day +14, threat memory retention was tested under 135 
extinction, ie. without reinforcement. Afterwards, US was presented again in a re-learning test (not shown). PSR: pupil size responses. SCR: 136 
skin conductance responses. HPR: heart period responses. 137 
Power analysis 138 
Power analysis was based on a pilot study with the same setup (Khemka et al., 2017b) (see 139 
(Bach et al., 2018a) for details). A sample size of N = 74 was required to achieve 80% power 140 
to detect at least 50% reduction in threat memory at an alpha rate of 0.05. We recruited N = 141 
80 participants to allow for attrition.  142 
Study medication 143 
Drug production and dosage: The study medication was doxycycline, brand name 144 
Vibramycin® (Pfizer). A GMP-licensed pharmacy (Kantonsapotheke Zürich) manufactured, 145 
blinded and randomized the study medication separately for males and females; mannitol 146 
was used as placebo. Randomisation code was broken after the last participant completed 147 
the study, and after all data were checked for consistency. The study dose of 200 mg is the 148 
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smallest antibiotic dose recommended by the manufacturer and the same dose that yielded 149 
a 60% reduction in threat memory consolidation in a previous report (Bach et al., 2018a).  150 
Timing of the reminder: In healthy individuals, plasma tmax of doxycycline preparations is on 151 
the order of around 2 h, although not reported in humans for the galenic formulation used 152 
here (Gschwend et al., 2007). Similarly, in individuals treated for Lyme disease, plasma tmax 153 
on treatment day 13 was between drug measurements taken at 0 and 2 h for most 154 
individuals, and between measurements taken at 2 and 4 h for the remaining ones (Karlsson 155 
et al., 1996). Doxycycline crosses the blood-brain barrier and is used for treatment of Lyme 156 
disease. In patients treated for this condition, doxycycline was detectable in CSF 2-3 h after 157 
ingestion on treatment days 5-8 (Dotevall and Hagberg, 1989), and 4 hours after oral 158 
ingestion on treatment day 13 (Karlsson et al., 1996); both studies report only one CSF 159 
measurement. In patients with schizophrenia, doxycycline was detectable in CSF 4 h after 160 
ingestion on treatment day 1 (Mento et al., 1969). In mice, repeated measurement of CSF 161 
levels revealed a CSF tmax of 4 or 6 h after intraperitoneal treatment, depending on the dose, 162 
with very little change between 4 and 6 h (Lucchetti et al., 2019). In a previous study, we had 163 
started threat memory acquisition after about 3.5 h (Bach et al., 2018a). Here, we scheduled 164 
the memory reminder after 3.5 h for consistency.  165 
Timing of the retention test: The drug's half-life is approximately 16 hours according to 166 
manufacturer's information; such the drug was cleared by more than 99.9% at the retention 167 
test 7 days after ingestion.  168 
Experimental procedure 169 
Screening visit 1 (day -7 to day -1): Study procedure is summarised in Figure 1b. On visit 1, 170 
we determined US intensity and tolerance to startle sounds, and performed medical 171 
examination to check exclusion criteria (Bach et al., 2018a).  172 
Acquisition visit 2 (day 0): Acquisition visit 2 took part between 08.00 and 15.30. 173 
Participants filled in the German translations of the State-Trait Anxiety Inventory (state: X1, 174 
trait: X2) (Laux et al., 1981) and Beck's Depression Inventory (Hautzinger et al., 1994) 175 
followed by the threat learning protocol. First, we re-calibrated US intensity using the same 176 
random procedure as on screening visit 1. Participants then trained the colour/response key-177 
mapping in blocks of 6 balanced CS, until they pressed the correct key in 5 out of 6 trials in 178 
one block (see Table 1 for the average number of training blocks required). This was 179 
followed by a standard discriminant delay threat conditioning paradigm with 45 trials (15 CS-180 
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, 15 CSr+, 15 CS+) in 1 block (Figure 1c). Both CS+ co-terminated with an electric stimulation 181 
as aversive US (see Stimuli and recordings) in 50% of trials. Trial sequence was randomly 182 
balanced for each participant, with the restriction that the first trial of each phase was 183 
always a reinforced CS+, the first six trials of each phase included each CS exactly twice, and 184 
that there could not be more than 5 instances of the same CS and 4 instances of US, or US 185 
omission, in a row. As an incidental task, participants were instructed to press one of three 186 
cursor keys on a standard keypad to indicate CS colour. We identified two outlier 187 
participants in the acquisition session: one (later treated with doxycycline) required an 188 
unusually high number of 7 training blocks (maximum for the rest of the sample: 3) and one 189 
(later treated with placebo) had an usually low accuracy of 56% in the incidental task. We 190 
conservatively retained these in the analysis but note that results of the primary analysis did 191 
not change if they were excluded.  192 
Reminder visit 3 (day +7): This visit took place between 08.00 and 17.00, with the reminder 193 
procedure finished before 16.00. Participants were verbally screened for health issues and 194 
ingested the study medication. During a 210-minute absorption interval, they were kept 195 
under surveillance of study staff. They were then attached to all electrodes, including the US 196 
electrode in the same location as on visit 2. Participants were instructed that they might 197 
receive US, but that CS/US contingency was determined by the computer and unknown to 198 
the study assistant. They saw one reminder CSr+ without reinforcement. This procedure 199 
would induce a learning-theoretic prediction error, which has been suggested crucial to 200 
engage re-consolidation (Sevenster et al., 2013). The use of a single reminder trial in cue 201 
conditioning is in line with previous human work (Kindt et al., 2009; Schiller et al., 2010) and 202 
has been suggested suitable for engaging molecular re-consolidation (as opposed to 203 
extinction) processes in rats (Merlo et al., 2014). The timing of the reminder session, 7 days 204 
after acquisition, was chosen to facilitate subject scheduling. We note that re-consolidation 205 
blockade of 1 week- and even 3 week-old memories has been demonstrated in mice (Suzuki 206 
et al., 2004). After the reminder, all electrodes were removed, and participants watched a 207 
pre-selected 10 minute cartoon movie episode with subtitles and without audio. This 208 
procedure is in line with previous human work (Schiller et al., 2010), and was chosen to bring 209 
cognitive effort immediately after the reminder under experimental control. This was 210 
followed by a 60-minute neuropsychological assessment to investigate the impact of 211 
doxycycline on other cognitive functions, which will be reported elsewhere.  212 
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Retention visit 3 (day +14): Participants were attached to all electrodes, including the US 213 
electrode in the same location as on visit 2. They were then instructed that they might 214 
receive US, but that CS/US contingency was determined by the computer and unknown to 215 
the study assistant. They saw 45 CS (15 CS-, 15 CSr+, 15 CS+) in randomly balanced order, 216 
and heard a startle probe 3.5 s after onset of all CS, but never received a US. Note that the 217 
motoric startle response makes psychophysiological data other than startle eyeblink 218 
responses from this session unusable. Immediately afterwards, we measured re-learning 219 
over 90 trials by co-terminating 50% of CS+ with a US, without startle sounds. US delivery 220 
was not tested before re-learning, in order to avoid re-instatement. Although US electrode 221 
location was controlled by measuring its distance from palpable carpal bones, minute 222 
differences in attachment can lead to diminished US perception. Seven participants (5 223 
doxycycline, 2 placebo; Fisher's exact test, p = .26) showed no unconditioned SCR to the 224 
shock, including three participants who reported in the final US intensity assessment that 225 
they did not feel any US during re-learning at all. One of these seven participants was 226 
already excluded due to suspected alcohol consumption; the other six were excluded for 227 
analysis of psychophysiological data in this session only. The first CS+ in this session was 228 
always reinforced, such that the first data point available for each CS+ was recorded after 229 
the first US. 230 
 231 
Stimuli and recordings 232 
Conditioned stimuli: CS were isoluminant coloured triangles presented for 4 s, while the 233 
screen was grey during the inter trial interval, randomly determined to be 7 s, 9 s, or 11 s. CS 234 
colours were (RGB values) orange (255, 176, 0), violet (255, 125, 255) and turquoise (0, 255, 235 
255), while the background was grey (179, 179, 179) with a white fixation cross. 236 
Unconditioned stimulus: The unconditioned stimulus (US) was a 500 ms train of 250 237 
electrical square pulses with an individual pulse duration of 0.2 ms, delivered on 238 
participants’ dominant forearm through a pin-cathode/ring-anode configuration with a 239 
constant current stimulator (Digitimer DS7A, Digitimer, Welwyn Garden City, UK). The 240 
current was set such that perceived shock intensity was around 90% of the pain threshold. 241 
We initially (visit 1) estimated the pain threshold during two phases. First, the intensity was 242 
increased from being unperceivable to a painful level. This was set as upper limit for all 243 
following perception tests, in which participants were asked to rate the perceived intensity 244 
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of 14 stimuli with different currents, which participants rated on a scale from 0 (not 245 
perceived) to 10 (clearly painful). Ratings were interpolated to estimate the current that the 246 
participant would have been rated as 90%. This current was then individually adjusted to 247 
yield a clearly discomforting but not painful stimulus. US electrode positioning across visits 248 
was ensured by recording distance from the (palpable) carpal bones. On acquisition visit 2, 249 
US perception was controlled with 14 stimuli of random intensity before threat memory 250 
acquisition. Stimulation strength was modified if necessary to yield a clearly discomforting 251 
but not painful stimulus. On reminder visit 3, US electrodes were attached and the 252 
stimulator was turned on, but no US were delivered. On retention visit 4, US electrodes were 253 
attached and no US were delivered before the tasks started. In both acquisition visit 2 and 254 
retention visit 4, pain perception was controlled after the task using 14 random stimuli. For 255 
part of the sample, different random stimuli were used in different assessments. For those 256 
participants that received the same random stimuli across two subsequent assessments, 257 
perceived US intensity decreased from beginning to end of acquisition visit 2 (t(43) = -2.6, 258 
p = .012) and from end of acquisition visit 2 to end of re-learning on visit 4 (t(67) = -4.5, p < 259 
.001; excluding 6 participants who did not show a SCR to the US on visit 4) with no difference 260 
between placebo and drug group (see table 1).  261 
Startle probes: In accordance with current recommendations (Blumenthal et al., 2005) and 262 
our own previous work (Khemka et al., 2017b), white noise bursts (loudness: 102 dB, 263 
duration: 40 ms, measured rise and fall time: < 2 ms, sampling frequency 44.1 kHz), were 264 
used as startle probes and delivered via headphones (Sennheiser HD 201, Germany), using 265 
the PC's inbuilt sound card (Realtek high definition audio) and an external sound amplifier 266 
(K4102, Velleman, Belgium). Sound volume was determined offline using a white noise 267 
sound of 2 s duration and a sound level meter (SL-200, Voltcraft, Germany). Sound onset 268 
was controlled by recording the output of the sound card together with EMG, and all 269 
analyses relate to the measured startle sound onset. 270 
Outcome measures: Preregistered primary outcome measure was startle potentiation over 271 
the entire retention test, measured as startle eye blink response (SEBR) in the same way as 272 
in a previous report (Bach et al., 2018a). There were no missing data in the primary 273 
outcome. Preregistered secondary outcome measures were skin conductance responses 274 
(SCR) and heart period responses (HPR, ie. conditioned bradycardia) during acquisition and 275 
re-learning. We also recorded and analysed pupil size because of its high fidelity (Korn et al., 276 
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2017) and because we had - after finalizing the pre-registration - demonstrated that PSR may 277 
be more closely related to US prediction than SCR (Tzovara et al., 2018).  278 
Psychophysiological recordings: The experiment took place in a dark, soundproof chamber. 279 
Participants placed their head on a chin rest at a distance of 70 cm from the monitor (Dell 280 
P2012H, 20” set to an aspect ratio of 5:4, 60 Hz refresh rate). SEBR were recorded using 281 
electromyogram from the orbicularis oculi muscle of participants’ right eye and two 4 mm 282 
Ag/AgCl cup electrodes filled with high-conductance gel. One of them was placed 10 mm 283 
below the lower eyelid in line with the pupil in forward gaze and the other on the external 284 
canthus, at a distance of 10 mm from the first (Blumenthal et al., 2005). Electromyogram 285 
was amplified with a Colbourn isolated bioamplifier (V75-11, Colbourn Instruments, 286 
Whitehall, PA, US). Skin conductance was recorded from the thenar/hypothenar of 287 
participants' left hand, using 8 mm Ag/AgCl cup electrodes (EL258, Biopac Systems Inc., 288 
Goleta, CA, US) and 0.5% NaCl gel (GEL101, Biopac) (Hygge and Hugdahl, 1985). Skin 289 
conductance signal was amplified with an SCR coupler/amplifier (V71-23, Coulbourn 290 
Instruments). All data were digitised at 1000 Hz using a DI-149 A/D card (Dataq Instruments, 291 
Akron, OH, US), and recorded with Windaq (Dataq Instruments) software. We recorded pupil 292 
area and gaze direction for both eyes with an EyeLink 1000 System (SR Research, Ottawa, 293 
ON, Canada) situated 47 cm away from the participant's eyes. The sampling rate was 500 Hz. 294 
To calibrate gaze direction, we used the 9-point protocol implemented in the EyeLink 1000 295 
software.  296 
Psychophysiological modelling 297 
For psychophysiological analysis, we used a Matlab toolbox for psychophysiological 298 
modelling, PsPM (version 4.0.2 r575, pspm.sourceforge.net) (Bach and Friston, 2013; Bach et 299 
al., 2018b).  300 
SEBR: Electromyogram processing was performed in the same way as in a previous report 301 
(Bach et al., 2018a), using the most sensitive method from a previous methodological 302 
comparison in the same setup (Khemka et al., 2017b). We band pass filtered the 303 
electromyogram signal with a 4th order Butterworth band pass filter (50-470 Hz), and applied 304 
a notch filter to remove 50 Hz harmonics. Filtered electromyogram data were rectified and 305 
smoothed with a 3 ms (53.05 Hz) 4th order Butterworth low pass filter. We then inverted a 306 
psychophysiological model that quantifies, for each trial, amplitude of the SEBR by linear 307 
regression onto a canonical SEBR with variable onset (Khemka et al., 2017b). Recorded 308 
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sound output was used as event marker. Differences in electrode impedance and muscle 309 
anatomy will result in a multiplicative scaling of the true SEBR. We thus normalised data by 310 
dividing each participant's single-trial SEBR estimates through the mean SEBR in CS- trials in 311 
the same way as in our previous report (Bach et al., 2018a). 312 
PSR: Eye blinks and saccades were detected by the online parsing algorithm of the eye 313 
tracker and excluded as missing data. Periods during which gaze direction was outside a box 314 
with 5° visual angle around the screen center were excluded as well. The pupil with fewer 315 
missing data points was used for subsequent analysis. Missing data points were linearly 316 
interpolated for filtering and ignored during model inversion. A trial was excluded if there 317 
were fewer than 50% available data points during the 10 s following CS onset. This 318 
procedure excluded, across all participants 40 trials (1.1%) from acquisition, and 72 (0.4%) 319 
from re-relearning. No participant had more than 35% missing trials in any session. To 320 
estimate the anticipatory pupil response, we used a single-trial general linear convolution 321 
model (GLM) after down sampling the data to 250 Hz (Korn et al., 2017).  322 
SCR: SCR data were visually inspected by a rather blind to placebo/doxycycline condition, 323 
and artefact periods (temporary electrode detachment or signal clipping) were excluded. 324 
Artefact periods shorter than 2 s were linearly interpolated for filtering and ignored for 325 
model inversion. If longer artefact periods fell into a trial, then this trial was excluded. No 326 
SCR data were not available for 1 participant during re-learning (placebo), due to electrode 327 
detachment. For the acquisition session, we further removed (across participants) 2 trials 328 
(0.05%). SCR data were then filtered with a 1st order bidirectional band-pass Butterworth 329 
filter (cut-off frequencies: 0.0159 Hz - 5 Hz, using interpolation for artefact periods), and 330 
down-sampled to 10 Hz. Resulting traces were analysed by non-linear inversion of a PsPM 331 
that describes the anticipatory and evoked SCR (Bach et al., 2010a; Staib et al., 2015) under 332 
a canonical response function (Bach et al., 2009; Bach et al., 2010b; Gerster et al., 2017). 333 
Specifically, a fixed-dispersion response at CS onset (with latency between 0-2 s) and a fixed-334 
latency response at (potential) US onset were estimated for each trial. The inversion 335 
algorithm was not informed about trial type or the presence of an US. This method has been 336 
successfully used for quantifying threat memory in similar studies setups (Bach et al., 2010a; 337 
Staib et al., 2015; Bach et al., 2018a; Staib and Bach, 2018; Tzovara et al., 2018). We included 338 
only non-reinforced trials in the analysis to avoid any contamination by US responses.  339 
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HPR: We detected R-spikes in the ECG using a modified Pan-Tompkins algorithm 340 
implemented in PsPM (Paulus et al., 2016). Inter beat interval was mapped onto the time 341 
point of the following R spike, and values outside 400 ms and 1200 ms (corresponding to a 342 
heart rate between 50-150 bpm) excluded. Heart period was then linearly interpolated with 343 
10 Hz sampling frequency and filtered with a 4th order bidirectional band-pass Butterworth 344 
filter (cut-off frequencies: 0.015 Hz - 0.5 Hz). To estimate the anticipatory pupil response, we 345 
used a condition-wise general linear convolution model (Castegnetti et al., 2016).  346 
Statistical analysis 347 
Statistical analysis was done in R (www.r-project.org), version 3.3.1, using the R function 348 
aov() for ANOVAs and R package lme4, version 1.1.15, was for linear mixed effects (LME) 349 
models together with package lmerTest for Sattertwaithe approximation to degrees of 350 
freedom (Luke, 2017). We analysed trial-wise response estimates (SEBR, PSR, SCR) in LME 351 
models. For PSR and SCR, only trials without US entered analysis. This model can deal with 352 
unbalanced data such that exclusion of individual trials is unproblematic. LME models 353 
included fixed effects for drug, CS, drug x CS, and for the effect of time in retention and re-354 
learning (trial number across CS for retention and within CS for re-learning), as well as their 355 
interactions, together with a random intercept (R model formula: startle ~ drug*CS*time, 356 
random = 1 |subject). Including other random effects rendered the models inestimable. 357 
Fixed effects statistics were extracted using the function anova(). Condition-wise heart 358 
period was tested in a standard repeated-measures ANOVA and fixed effects tested against 359 
pooled error variance. Control measures were tested for group differences with 360 
independent samples t-tests, without correction for multiple comparisons.  361 
 362 
Cross-validation analysis of our main result was performed using a simplified ANOVA model 363 
that does not take into account the randomised trial sequence. We first replicated the main 364 
result using a drug x CS+/CS- x time (trial number within CS) ANOVA, using the R package 365 
ezANOVA, version 4.4-0. We then predicted each participant's CS+/CS- difference from the 366 
drug factor, in a 3-fold cross-validation scheme. We randomly partitioned our participant 367 
sample into 3 equally sized folds. Because the partitioning affects the results, the procedure 368 
was repeated on 10 random partitionings. We trained a linear model on two folds, and 369 
predicted the CS+/CS- difference in the third fold. Residual variance proportion was 370 
computed as sum of squared prediction error, divided by the number of data points, and by 371 
Bach et al: MMP inhibitor doxycycline reduces memory plasticity 
 14 
the variance of the data. We then randomly permuted participants' drug labels 1000 times 372 
and repeated the procedure. For each permutation, residual variance proportion was 373 
averaged over the 3 folds and the 10 partitionings. A p-value was computed as the rate by 374 
which the residual sum of squares in the random permutations was smaller than when using 375 
the correct drug labels.     376 
 377 
Data and code availability 378 
All anonymised data are available in a public repository 379 
(https://doi.org/10.5281/zenodo.3441715). All specific code used to generate the results 380 
and figures is available on www.doi.org/10.17605/OSF.IO/UJHXW. 381 
  382 
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Results 383 
Acquisition of CS/US association before drug application 384 
On acquisition visit 2, participants performed a discriminant delay threat conditioning task 385 
(see Figure 1c) in which two CS+ co-terminated with an aversive electrical stimulation in 50% 386 
of trials, while a single CS- was never reinforced. Accuracy in an incidental task (see Table 1) 387 
was (non-significantly) higher for the doxycycline group and was subsequently modelled as a 388 
covariate to corroborate our primary analysis of memory retention.  389 
 390 
 391 
Figure 2. Learning indices during threat acquisition on day 0. AB: Trial-by-trial PSR and SCR data, interpolated with last observation carried 392 
forward. C: PSR last 15 trials interpolated and averaged. D: SCR last 15 trials interpolated and averaged. E: HPR across all trials. CS+r is the 393 
CS+ that is retrieved on day +7. CS+n is not retrieved. Error bars refer to between-subject SEM of condition-wise estimates after correcting 394 
for the overall participant mean. Scatter plots show individual participants' response, after correcting for the overall participant mean. PSR: 395 
pupil size responses. SCR: skin conductance responses. HPR: heart period responses. ** p < .01; ** p < .001 (see table 2) 396 
 397 
Participants learned the CS/US association as indicated by stronger PSR, SCR, and HPR, to 398 
both CS+ than to CS- (see Table 2, Figure 2). PSR (but not SCR or HPR) CS+/CS- differences 399 
were higher for the placebo than for the doxycycline group. Also, PSR and SCR (but not HPR) 400 
to CS+r were higher than to CS+n, although both CS+ had the same global reinforcement 401 
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rate, and were randomised in terms of position in the trial sequence and local reinforcement 402 
rate.  403 
 404 
However, analysing just the final 15 trials of the acquisition session revealed a clear CS+/CS- 405 
difference with no difference between the two CS+ (see table 2) and no difference between 406 
the two groups. Thus, we conclude that both CS+ were ultimately associated with US to the 407 
same extent in both experimental groups. To account for any possible differences between 408 
the groups, overall CS+/CS- difference in PSR (across all trials) was subsequently modelled as 409 
a covariate to corroborate our primary analysis of memory retention.  410 
 411 
Table 2: Linear mixed effects models (trial-wise PSR and SCR) and ANOVA (condition-wise HPR) results for the acquisition phase on day 0, 7 412 
days before drug ingestion. PSR: pupil size responses. SCR: skin conductance responses. HPR: heart period responses. 413 
F df p 
PSR: group 0.49 1, 78.3 0.49 
PSR: CS+ vs. CS- 150.89 1, 3390.8 < .001 
PSR: group x (CS+ vs. CS-) 3.89 1, 3390.8 0.049 
PSR: CS+r vs. CS+n 4.19 1, 2226.3 0.041 
PSR: group x (CS+r vs. CS+n) 1.1 1, 2226.3 0.29 
PSR last 15 trials: CS+ vs. CS- 90.99 1, 1101.6 < .001 
PSR last 15 trials: group x (CS+ vs. CS-) 2.68 1, 1101.6 0.1 
PSR last 15 trials: CS+r vs. CS+n 0.06 1, 713.9 0.8 
PSR last 15 trials: group x (CS+r vs. CS+n) 0 1, 713.9 1 
SCR: drug 0.69 1, 76 0.41 
SCR: CS+ vs. CS- 15.39 1, 2182 < .001 
SCR: group x (CS+ vs. CS-) 0.26 1, 2182 0.61 
SCR: CS+r vs. CS+n 6.97 1, 1012 0.008 
SCR: group x (CS+r vs. CS+n) 0.77 1, 1012 0.38 
SCR last 15 trials: CS+ vs. CS- 7.38 1, 669.1 0.007 
SCR last 15 trials: group x (CS+ vs. CS-) 1.23 1, 669.1 0.27 
SCR last 15 trials: CS+r vs. CS+n 0.05 1, 666.3 0.83 
SCR last 15 trials: group x (CS+r vs. CS+n) 0.26 1, 666.3 0.61 
HPR: group 1.54 1, 76 0.22 
HPR: CS+ vs. CS- 15.51 1, 154 < .001 
HPR: group x (CS+ vs. CS-) 0 1, 154 0.94 
HPR: CS+r vs. CS+n 0 1, 76 0.95 
HPR: group x (CS+r vs. CS+n) 2.46 1, 76 0.12 
 414 
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Increased CS+ retention one week after CS+r retrieval under doxycycline  415 
Seven days after acquisition visit 2, participants ingested placebo or 200 mg doxycyline. 416 
After 3.5 hours they were exposed to an unreinforced CS+r. Then all electrodes were 417 
detached and they watched a 10-minute cartoon movie, followed by a neuropsychological 418 
assessment. Seven days later (i.e., on day +14), we measured threat memory retention 419 
under extinction  (ie. with no US presentation) as our primary outcome (see Figure 3a, Table 420 
3). Fear-potentiated startle was measured as SEBR to acoustic startle probes on each of 45 421 
extinction trials, and analysed in a LME model with trial number as predictor across CS types, 422 
to account for the individually randomised trial sequence.  423 
 424 
 425 
Figure 3. SEBR (startle eye-blink responses) during threat memory retention on day +7. A: averaged over all trials. Inset: Same data overlaid 426 
with individual participants' responses, after correcting for the overall participant mean. BC: Trial-by-trial data, interpolated with last 427 
observation carried forward. Insets: Early (first 15 trials) and late (last 15 trials). To account for the random trial sequence and therefore 428 
unbalanced distribution of data points, the insets show difference from an exponential habituation curve, fitted across all trials per 429 
participant. A LME with exponential habituation (instead of the omnibus effect of trial) yielded the same result pattern as shown in table 3. 430 
CS+r is the CS+ that is reminded on day +7. CS+n is not retrieved. Error bars refer to between-subject SEM of condition-wise estimates after 431 
correcting for the overall participant mean. * p < .05 432 
 433 
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In the placebo group, we observed extinction learning (CS x trial interaction, see Figure 3b 434 
insets) and startle habituation (main effect trial). There was no difference between CS+r and 435 
CS+n in this group, or time x CS+r/CS+n interaction, suggesting that the experimental 436 
procedure, which involved a 60-minute neuropsychological test after the reminder, had no 437 
appreciable impact on differential re-consolidation. The doxcycline group showed no 438 
evidence for extinction learning and instead a persistent CS+/CS- difference, again with no 439 
difference between CS+r and CS+n (for statistics see Table 3). 440 
 441 
Comparing the two groups in our primary analysis revealed in doxycycline-treated 442 
individuals a larger SEBR overall and in particular for CS+ (main effect drug, drug x CS+ 443 
interaction). This interaction was clearly visible on integrated EMG traces, suggesting that 444 
this difference is not due to any possible effects of doxycycline treatment on the timing or 445 
shape of the startle response which could bias its scoring. Across both groups, SEBR 446 
habituated (main effect trial), and the initially higher SEBR under CS+ relative to CS- 447 
extinguished over time (interaction CS+ x trial). There was no overall difference between 448 
CS+r and CS+n, and no impact of doxycycline on this difference. Because of evidence for 449 
differential learning in the two groups already on day 1 (as indexed by CS+/CS- difference in 450 
PSR), we included this parameter into the model as a covariate. This replicated the drug x 451 
CS+ interaction and revealed no significant effect involving the covariate. The same result 452 
was observed in a model that included accuracy during initial learning as covariate. Thus, 453 
there was no evidence to suggest that our main result was better explained by group 454 
differences in initial learning or performance.  455 
 456 
Because this significant result stands in contrast to our prior expectations, there is an 457 
increased risk that it represents a false positive and indeed doxycycline has no systematic 458 
effect in the population. We therefore used cross-validation and investigated how well the 459 
observed drug x CS+ interaction generalised within the sample. To facilitate this analysis, we 460 
did not take into account the randomised trial sequence. We first replicate our main result in 461 
an drug x CS+/CS- x trial (per CS) ANOVA (drug x CS+: F(1, 76) = 7.40, p = .008). Cross-462 
validation analysis showed that a participant's CS+/CS- difference could be predicted from 463 
whether a participant had taken drug or placebo, using a model that had not seen this 464 
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participant's data (random permutation test: p < .001). This suggests that the observed drug 465 
x CS+/CS- is consistent within our sample. 466 
 467 
Table 3: Linear mixed effects models results for the retention test, 7 days after drug ingestion/retrieval and 14 days after acquisition. SEBR: 468 
startle eye-blink responses. 469 
F df p 
SEBR: drug 4.32 1, 87.7 .041 
SEBR: CS+ vs. CS- 1.43 1, 3254.7 .23 
SEBR: Trial 33.45 44, 3264.8 < .001 
SEBR: drug x (CS+ vs. CS-) 4.39 1, 3254.7 .036 
SEBR: drug x trial 0.87 44, 3264.8 .72 
SEBR: trial x (CS+ vs. CS-) 1.5 44, 3314.7 .018 
SEBR: drug x trial x (CS+ vs. CS-) 1.04 44, 3314.7 .4 
SEBR: CS+r vs. CS+n 1.06 1, 2086.6 .3 
SEBR: drug x (CS+r vs. CS+n) 0.24 1, 2086.6 .62 
SEBR: drug x trial x (CS+r vs. CS+n) 1.01 44, 2137.8 .46 
SEBR: CS+ vs. CS- (Placebo) 0.41 1, 1671.6 .52 
SEBR: Trial (Placebo) 19.51 44, 1677.2 < .001 
SEBR: trial x (CS+ vs. CS-) (Placebo) 1.68 44, 1703.9 .004 
SEBR: CS+ vs. CS- (Doxycycline) 5.37 1, 1583.2 .021 
SEBR: Trial (Doxycycline) 14.8 44, 1587.1 < .001 
SEBR: trial x (CS+ vs. CS-) (Doxycycline) 0.9 44, 1608.9 .67 
 470 
 471 
Reduced CS+ re-learning one week after CS+r retrieval under doxycycline  472 
Next, we analysed the re-learning session, which immediately followed the retention session 473 
and always started with a reinforced CS+ trial (Figure 4, Table 4). We observed larger PSR 474 
and SCR to CS+ versus CS- in the placebo group than in the doxycycline group (interaction 475 
drug x CS) and no difference between, or interaction with, CS+r and CS+n. SCR were overall 476 
higher after doxycycline than placebo treatment. There was no impact of drug on HPR. 477 
Across both groups, PSR, SCR and HPR were higher for CS+ than CS-. Initially high PSR and 478 
SCR decayed over time (main effect trial).  479 
 480 
Separating the groups, we observed higher PSR (F(1, 3223.2) = 235.2, p < .001) and SCR (F(1, 481 
2064.0) = 28.5, p < .001) to CS+ versus CS- in the placebo group, and higher PSR (F(1, 2875.9) 482 
= 116.8, p < .001) but not SCR (F(1, 1887.0) = 2.7, p = .10) to CS+ versus CS- in the 483 
doxycycline group. There was no CS+/- x trial interaction in the placebo group, which is 484 
expected given that the first available data point refers to a trial after at least one US. 485 
 486 






Figure 4. Threat memory measures during re-learning on day +14. ADF: PSR, B: HPR, CEG: SCR. AC: Trial-wise estimates, averaged over all 491 
90 trials. B: condition-wise estimates across all 90 trials. D-G: Trial-by-trial data, interpolated with last observation carried forward. Trials 492 
for which less than 10 participants provided data (due to the random trial sequence) are not plotted. Reinforced trials were not analysed; 493 
first trial was always reinforced. CS+r is the CS+ that is retrieved on day +7. CS+n is not retrieved. Error bars refer to between-subject SEM 494 
of condition-wise estimates after correcting for the overall participant mean. Scatter plots show individual participants' response, after 495 
correcting for the overall participant mean. PSR: pupil size responses. SCR: skin conductance responses. HPR: heart period responses. *** p 496 
< .001 497 
 498 
  499 
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Table 4: Linear mixed effects models (trial-wise PSR and SCR) and ANOVA (condition-wise HPR) results for the re-learning test, 7 days after 500 
drug ingestion/reminder and 14 days after acquisition. PSR: pupil size responses. SCR: skin conductance responses. HPR: heart period 501 
responses. 502 
F df p 
PSR: drug 0.45 1, 71.5 0.51 
PSR: CS+ vs. CS- 316.17 1, 6279.2 < .001 
PSR: trial 36.25 15, 6282.6 < .001 
PSR: drug x (CS+ vs. CS-) 19.46 1, 6279.2 < .001 
PSR: drug x trial 1.45 15, 6282.6 0.12 
PSR: trial x (CS+ vs. CS-) 0.98 14, 6281.4 0.47 
PSR: drug x trial x (CS+ vs. CS-) 0.96 14, 6281.4 0.5 
PSR: CS+r vs. CS+n 1.46 1, 4148.7 0.23 
PSR: drug x (CS+r vs. CS+n) 0.04 1, 4148.7 0.83 
PSR: trial x (CS+r vs. CS+n) 0.92 15, 4155.5 0.54 
PSR: drug x trial x (CS+r vs. CS+n) 1.18 15, 4155.5 0.28 
SCR: drug 4.03 1, 69 0.049 
SCR: CS+ vs. CS- 20.93 1, 4131 < .001 
SCR: trial 23.04 14, 4131 < .001 
SCR: drug x (CS+ vs. CS-) 5.1 1, 4131 0.024 
SCR: drug x trial 1.33 14, 4131 0.18 
SCR: trial x (CS+ vs. CS-) 0.81 14, 4131 0.66 
SCR: drug x trial x (CS+ vs. CS-) 0.41 14, 4131 0.97 
SCR: CS+r vs. CS+n 2.79 1, 2001 0.095 
SCR: drug x (CS+r vs. CS+n) 1.03 1, 2001 0.31 
SCR: trial x (CS+r vs. CS+n) 0.8 14, 2001 0.67 
SCR: drug x trial x (CS+r vs. CS+n) 0.78 14, 2001 0.69 
HPR: drug 0.39 1, 70 0.54 
HPR: CS+ vs. CS- 18.11 1, 142 < .001 
HPR: drug x (CS+ vs. CS-) 0.62 1, 142 0.43 
HPR: CS+r vs. CS+n 0.63 1, 70 0.43 
HPR: drug x (CS+r vs. CS+n) 0 1, 70 0.95 
     
  503 
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Discussion 504 
In this study, we sought to demonstrate that the non-selective MMP inhibitor doxycycline 505 
disrupts threat memory re-consolidation, as a proof-of-principle for its clinical application. 506 
We based this hypothesis on the fact that many molecular and cellular features of 507 
consolidation and re-consolidation are shared, and on our previous observation that 508 
doxycycline disrupts threat memory acquisition/consolidation. However, contrary to our 509 
expectations, threat memory reminder under doxycycline had no specific impact on the 510 
reminded CS+. Instead, the manipulation appeared to globally increase CS+/CS- 511 
discriminative memory during retention test, compared to placebo. This increased 512 
discriminative memory was consistent within our sample, as demonstrated using cross-513 
validation. Tentatively, this may be due to reduced extinction learning during the retention 514 
test, in those individuals that were reminded under doxycycline, although a direct 515 
comparison of the extinction trajectory between the two groups was not significant. 516 
Furthermore, subsequent threat re-learning was reduced in those that were reminded under 517 
doxycycline. Taken together, it appears that doxycycline may globally impair memory one 518 
week later. While unexpected, this result offers important insights into the potential role of 519 
MMPs in memory. We discuss possible scenarios that could explain our current and previous 520 
data (Bach et al., 2018a).  521 
 522 
Explaining the lack of a reminder-specific effect of doxycycline in the present data (but not 523 
global memory impairment), there is a possibility that MMP-9 is involved in consolidation, 524 
explaining our previous result (Bach et al., 2018a), but not in re-consolidation. Despite the 525 
conceptual similarity of consolidation and re-consolidation (McKenzie and Eichenbaum, 526 
2011) and overlap in the molecular pathways, important differences have also been pointed 527 
out (comprehensively reviewed in (Besnard et al., 2012). For example, norepinephrine 528 
antagonists (McGaugh, 2000; Debiec and Ledoux, 2004; Lonergan et al., 2013) and gamma-529 
aminobutyric acid agonists (Makkar et al., 2010) block both consolidation and re-530 
consolidation. Also, translational control in mTOR signalling-dependent manner (Roesler, 531 
2017), and transcriptional control through NF-κB downstream signaling (de la Fuente et al., 532 
2015) appear involved in consolidation and re-consolidation. On the other hand, an example 533 
for pathway dissociation is the involvement of brain-derived neurotrophic factor BDNF in 534 
consolidation but not re-consolidation, and of the transcription factor Zif268 in re-535 
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consolidation but not consolidation (Lee et al., 2004). Our data suggest that MMP-9 would 536 
be involved only in memory consolidation. In one rodent study, memory re-consolidation 537 
was attenuated by inhibiting MMP-9; however, that study did not support the otherwise 538 
well-established effect of MMP-9 inhibition on synaptic consolidation such that this result 539 
offers ambiguous evidence (Brown et al., 2009). As a limitation, doxycycline is an unspecific 540 
MMP inhibitor. There is evidence that MMPs other than MMP-9 are involved in learning and 541 
memory (Meighan et al., 2006; Conant et al., 2015), although the underlying signaling 542 
pathways and proteolytic targets are less well known, for mainly methodological reasons 543 
(Huntley, 2012). In case diverse MMPs have different, possibly even opposing, roles for 544 
consolidation, and/or for re-consolidation, then unspecific MMP inhibition could reveal 545 
results that are difficult to interpret. Overall, it appears that more work is needed in non-546 
human animals to establish the signaling pathway involved in memory consolidation, and 547 
the contribution of MMP-9. It has been suggested that an impact of MMP-9 on LTP involves 548 
its substrate CD44, a transmembrane protein and receptor for the ECM component hyaluron 549 
(Bijata et al., 2017). However, many other substrates of MMP-9 could potentially confer an 550 
impact on learning and memory as well. For example, dystroglycan, another transmembrane 551 
protein and part of ECM, has been reported as a MMP-9 substrate (Michaluk et al., 2007). 552 
Dystroglycan and dystrophin-dystroglycan complex are localized at hippocampal GABAergic 553 
synapses (Brunig et al., 2002).  Cell-specific loss of dystroglycan from hippocampal pyramidal 554 
cells leads to distinct loss of GABAergic CCK positive basket cell terminals, with defect in 555 
hippocampal theta oscillations  (Fruh et al., 2016). Theta oscillations have been associated 556 
with memory function in both rodents and humans (Hebscher et al., 2019), including threat 557 
memory retrieval (Seidenbecher et al., 2003; Khemka et al., 2017a; Tzovara et al., 2019). 558 
Doxycycline inhibition of MMP-9 could thus interfere with GABAergic transmission and alter 559 
network oscillations that are integral to cognition and memory.  560 
 561 
Regarding global memory impairment beyond the clearance of the drug (but not the lack of 562 
a reminder-specific effect), several explanations appear plausible. First, it is possible that 563 
MMP inhibition, and thus an impact of doxycycline on LTP, lasts for more than a week. 564 
Doxycyline is reported not only to inhibit MMP activity (Golub et al., 1991), but also MMP 565 
synthesis, reducing mRNA levels (Hanemaaijer et al., 1998). If doxycycline exerts this impact 566 
by blocking the ribosome, since ribosomal RNA has a turnaround time of more than two 567 
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weeks (Mathis et al., 2017), it is possible that full level of MMP translation is not achieved 568 
one week after doxycycline ingestion, leading to lingering reduction in LTP. More tentatively, 569 
it is also possible that the effects of MMP on memory are not (only) conferred via LTP but via 570 
other mechanisms, including the configuration of extracellular matrix. Indeed, doxycycline 571 
affects extracellular matrix structure (Palomino-Morales et al., 2016), and different 572 
structural components of the matrix are suggested to impact on memory (Gogolla et al., 573 
2009; Tsien, 2013; Happel et al., 2014; Banerjee et al., 2017). The turnaround time of the 574 
extracellular matrix is much longer than that of individual proteins (Tsien, 2013), thus 575 
explaining a long-lasting impact of doxycycline treatment. Finally, it is possible that 576 
doxycycline acts on memory via a pathway not involving MMP. For example, doxycycline 577 
induces apoptosis in cancer stem cells (Matsumoto et al., 2017) and may have the same 578 
impact on neuronal progenitor cells. This could explain an effect at least on hippocampal-579 
dependent memory, which would last longer than one week since adult new born neurons 580 
require around 28 days to proliferate after acquiring the status of neuronal progenitor cells 581 
from stem cells, migrate to the granular zone from the sub granular zone and send out 582 
dendrites to integrate into the network (Abrous and Wojtowicz, 2015). We note that our 583 
human data cannot disambiguate these possibilities and further in-vitro research will be 584 
required to answer this question. 585 
 586 
As a limitation, our conclusion that doxycycline induces a lasting memory impairment is 587 
partly based on impaired extinction learning after doxycycline treatment. This however is a 588 
tentative interpretation of our data, based on demonstrating globally stronger discriminative 589 
memory retention in doxycycline-treated individuals, together with evidence for extinction 590 
learning during the retention test in placebo-treated individuals, and lack of such evidence in 591 
doxycycline-treated individuals. However, a direct statistical comparison of extinction 592 
learning between both groups was not significant, such that this should be investigated in a 593 
larger sample. Measuring at least serum concentration of doxycycline could also help 594 
account for behavioural variability and thus increase the sensitivity of the assessment.  595 
 596 
Furthermore, the conclusion of a difference between doxycycline impact on consolidation 597 
and re-consolidation also merits replication. We note that demonstration of re-consolidation 598 
blockade in human threat conditioning has generally been more mixed than in non-human 599 
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animals, both regarding behavioural (Kredlow et al., 2016) and pharmacological 600 
interventions (Elsey et al., 2018). This may be due to suboptimal experimental circumstances 601 
as well as to large interindividual variability. We note that our power calculations were 602 
based on the best-case assumption of negligible variability of the true drug effect and 603 
variability only in the measurement. In case of non-negligible or even high variability across 604 
individuals, much larger sample sizes may be required. 605 
 606 
To summarize, we find no evidence of a specific impact of CS+ reminder under doxycycline 607 
on memory re-consolidation. Instead, we find a global impairment in extinction learning, and 608 
threat re-learning, in doxycycline-treated individuals, which lasted beyond the clearance of 609 
the drug.  610 
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